Diabetic and endocrine emergencies

Postgraduate Medical Journal

Volumn 83, Issue 976, 2007, Pages 79-86

  Kearney, T ^a   Dang, C ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CARBIMAZOLE; DEXAMETHASONE; FLUDROCORTISONE; GLUCOSE; HYDROCORTISONE; INSULIN; INSULIN LISPRO; LITHIUM CARBONATE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PHENTOLAMINE; PROPRANOLOL DERIVATIVE; PROPYLTHIOURACIL; SODIUM IODIDE; THIAMAZOLE;

ADRENAL INSUFFICIENCY; CLINICAL FEATURE; CLINICAL TRIAL; DIABETIC KETOACIDOSIS; DIET THERAPY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EMERGENCY CARE; ENDOCRINE DISEASE; FLUID RESUSCITATION; HOSPITAL ADMISSION; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPEROSMOLARITY; HYPERTENSIVE CRISIS; HYPOGLYCEMIA; HYPOPHYSIS APOPLEXY; LABORATORY TEST; LOW DRUG DOSE; MYXEDEMA; PHEOCHROMOCYTOMA; REVIEW; THYROID CRISIS; THYROIDECTOMY; UNITED KINGDOM; WORKLOAD;

ADRENAL INSUFFICIENCY; DIABETIC KETOACIDOSIS; EMERGENCIES; ENDOCRINE SYSTEM DISEASES; HUMANS; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; LABORATORY TECHNIQUES AND PROCEDURES; MYXEDEMA; PHEOCHROMOCYTOMA; PITUITARY APOPLEXY; THYROID DISEASES;

EID: 33847388865     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.049445     Document Type: Review

References (92)

1. Umpierrez GE, Woo W, Hagopian WA, et al. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care 1999;22:1517-23.
2. Balasubramanyam A, Zern JW, Hyman DJ, et al. New profiles of diabetic ketoacidosis: type 1 vs type 2 diabetes and the effect of ethnicity. Arch Intern Med 1999;159:2317-22.
3. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(Suppl 1):S94-102.
4. NHS Health and Social Care Information Centre. http://www.hesonline.nhs.uk/Ease (accessed 25 Oct 2006).
5. The EURODIAB IDDM Complications Study. Microvascular and acute complications in IDDM patients. Diabetologia 1994;37:278-85.
6. National Centre for Health Statistics. Detailed diagnosis and procedures: National Discharge Survey, 1995. Vital Health Stat 1997;13:130.
7. Basu A, Close CF, Jenkins D, et al. Persisting mortality in diabetic ketoacidosis. Diabet Med 1993;10:282-4.
8. Malone ML, Gennis V, Goodwin JS. Characteristics of diabetic ketoacidosis in older versus younger adults. J Am Geriatr Soc 1992;40:1100-4.
9. Matz R. Hyperosmolar nonacidotic diabetes (HNAD). In: Porte D Jr, Sherwin RS, eds. Diabetes mellitus: theory and practice. Amsterdam: Elsevier, 1997:845-60.
10. Ellemann K, Soerensen JN, Pedersen L, et al. Epidemiology and treatment of diabetic ketoacidosis in a community population. Diabetes Care 1984;7:528-32.
11. Polonsky WH, Andersen BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994;17:1178-85.
12. Felig P, Sherwin RS, Soman V, et al. Hormonal interactions in the regulation of blood glucose. Recent Prog Norm Res 1979;35:501-32.
13. Chiasson JL, Aris-Jilwan N, Belanger R, et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ 2003;168:859-66.
14. Campbell IW, Duncan LJ, Innes JA, et al. Abdominal pain in diabetic metabolic decompensation. Clinical significance. JAMA 1975;233:166-8.
15. Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:675-80.
16. De Boer SY, Masclee AA, Lam WF, et al. Effect of hvperglycaemia on gallbladder motility in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1994;37:75-81.
17. Umpierrez GE, Kelly JP, Navarrete JE, et al. Hyperglycemic crises in urban blacks. Arch Intern Med 1997;157:669-75.
18. Kitabchi AE, Wall BM. Diabetic ketoacidosis. Med Clin North Am 1995;79:9-37.
19. Kaminska ES, Pourmotabbed G. Spurious laboratory values in diabetic ketoacidosis and hyperlipidemia. Am J Emerg Med 1993;11:77-80.
20. Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 1983;57:177-80.
21. Carroll P, Matz R. Uncontrolled diabetes mellitus in adults: experience in treating diabetic ketoacidosis and hyperosmolar nonketotic coma with low-dose insulin and a uniform treatment regimen. Diabetes Care 1983;6:579-85.
22. Vinicor F, Lehrner LM, Karn RC, et al. Hyperamylasemia in diabetic ketoacidosis: sources and significance. Ann Intern Med 1979;91:200-4.
23. Yadav D, Nair S, Norkus EP, et al. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am J Gastroenterol 2000;95:3123-8.
24. Slovis CM, Mork VG, Slovis RJ, et al. Diabetic ketoacidosis and infection: leukocyte count and differential as early predictors of serious infection. Am J Emerg Med 1987;5:1-5.
25. Moss JM. Diabetic ketoacidosis: effective low-cost treatment in a community hospital. South Med J 1987;80:875-81.
26. May ME, Young C, King J. Resource utilization in treatment of diabetic ketoacidosis in adults. Am J Med Sci 1993;306:287-94.
27. Alberti KG, Hockaday TD, Turner RC. Small doses of intramuscular insulin in the treatment of diabetic "coma". Lancet 1973;2:515-22.
28. Sacks HS, Shahshahani M, Kitabchi AE, et al. Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion. Ann Intern Med 1979;90:36-42.
29. Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. N Engl J Med 1977;297:238-41.
30. Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 1986;105:836-40.
31. Lever E, Jaspan JB. Sodium bicarbonate therapy in severe diabetic ketoacidosis. Am J Med 1983;75:263-8.
32. Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 1983;57:177-80.
33. Wilson HK, Keuer SP, Lea AS, et al. Phosphate therapy in diabetic ketoacidosis. Arch Intern Med 1982;142:517-20.
34. Winter RJ, Harris CJ, Phillips LS, et al. Diabetic ketoacidosis. Induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am J Med 1979;67:897-900.
35. Hamblin PS, Topliss DJ, Chosich N, et al. Deaths associated with diabetic ketoacidosis and hyperosmolar coma. 1973-1988. Med J Aust 1989;151:1439, 441-2, 444.
36. Faigel DO, Metz DC. Prevalence, etiology, and prognostic significance of upper gastrointestinal hemorrhage in diabetic ketoacidosis. Dig Dis Sci 1996;41:1-8.
37. Bello FA, Sotos JF. Cerebral oedema in diabetic ketoacidosis in children. Lancet 1990;336:64.
38. Rosenbloom AL. Intracerebral crises during treatment of diabetic ketoacidosis. Diabetes Care 1990;13:22-33.
39. Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am 1995;79:39-52.
40. Oh MS, Carroll HJ, Uribarri J. Mechanism of normochloremic and hyperchloremic acidosis in diabetic ketoacidosis. Nephron 1990;54:1-6.
41. Madias NE, Homer SM, Johns CA, et al. Hypochloremia as a consequence of anion gap metabolic acidosis. J Lab Clin Med 1984;104:15-23.
42. Oh MS, Banerji MA, Carroll HJ. The mechanism of hyperchloremic acidosis during the recovery phase of diabetic ketoacidosis. Diabetes 1981;30:310-13.
43. Shorr RI, Ray WA, Daughterly JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157:1681-6.
44. Sampson MJ, Mortley S, Aldridge VJ. The East Anglian Ambulance Trust diabetes emergencies audit - numbers and demographics. Diabet Med 2006;23:P101.
45. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
46. Stephenson JM, Kempler P, Perin PC, et al. Is autonomic neuropathy a risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications Study. Diabetologia 1996;39:1372-6.
47. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993;42:1683-9.
48. Lingenfelser T, Buettner U, Martin J, et al. Improvement of impaired counterregulatory hormone response and symptom perception by short-term avoidance of hypoglycemia in IDDM. Diabetes Care 1995;18:321-5.
49. Boyle PJ, Schwartz NS, Shah SD, et al. Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. N Engl J Med 1988;318:1487-92.
50. Baker H, Horton A, Low P, et al. 'HYPOBOX' a practical aid in the management of hypoglycaemia in hospital. Diabet Med 2006;23:P186.
51. Forrest LV, Obuobie KO. Audit of hypoglycaemia management amongst junior doctors. Diabet Med 2006;23:P187.
52. Walls J, Ratcliffe WA, Howell A, et al. Parathyroid hormone and parathyroid hormone-related protein in the investigation or hypercalcaemia in two hospital populations. Clin Endocrinol (Oxford) 1994;41:407-13.
53. Mallette LE, Bilezikian JP, Heath DA, et al. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore) 1974;53:127-46.
54. Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 1987;102:958-66.
55. Paloyan D, Simonowitz D, Paloyan E, et al. Pancreatitis associated with primary hyperparathyroidism. Am Surg 1982;48:366- 8.
56. Benabe JE, Martinez-Maldonado M. Hypercalcemic nephropathy. Arch Intern Med 1978;138:777-9.
57. Goldfarb S, Agus ZS. Mechanism of the polyuria of hypercalcemia. Am J Nephrol 1984;4:69-76.
58. Manz F, Jaschke W, van Kaick G, et al. Nephrocalcinosis in radiographs, computed tomography, sonography and histology. Pediatr Radiol 1980;9:19-26.
59. Gatewood JW, Organ CH Jr, Mead BT. Mental changes associated with hyperparathyroidism. Am J Psychiatry 1975;132:129-32.
60. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. QJM 1981;50:473-81.
61. Bilezikian JP. Clinical review 51: management of hypercalcemia. J Clin Endocrinol Metab 1993;77:1445-9.
62. Body JJ, Borkowski A, Cleeren A, et al. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 1986;4:1177-83.
63. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-9.
64. Ljunghall S. Use of clodronate and calcitonin in hypercalcemia due to malignancy. Recent Results Cancer Res 1989;116:40-5.
65. Yu J, Papavasiliou V, Rhim J, et al. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs 1995;6:101-8.
66. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993;22:263-77.
67. Colebunders R, Bourdoux P, Bekaert J, et al. Determination of free thyroid hormones and their binding proteins in a patient with severe hyperthyroidism (thyroid storm?) and thyroid encephalopathy. J Endocrinol Invest 1984;7:379-81.
68. Brooks MH, Waldstein SS. Free thyroxine concentrations in thyroid storm. Ann Intern Med 1980;93:694-7.
69. Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid 1999;9:1167-74.
70. Hylander B, Rosenqvist U. Treatment of myxoedema coma-factors associated with fatal outcome. Acta Endocrinol (Copenhagen) 1985;108:65-71.
71. Hylander B, Rosenqvist U. Treatment of myxoedema coma-factors associated with fatal outcome. Acta Endocrinol (Copenhagen) 1985;108:65-71.
72. Rodriguez I, Fluiters E, Perez-Mendez LF, et al. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol 2004;180:347-50.
73. Holvey JN, Goodner G, Nicoloff JT, et al. Treatment of myxedema coma with intravenous thyroxine. Arch Intern Med 1964;113:89-96.
74. Burke CW. Adrenocortical insufficiency. Clin Endocrinol Metab 1985;14:947-76.
75. Stacpoole PW, Interlandi JW, Nicholson WE, et al. Isolated ACTH deficiency: a heterogeneous disorder. Critical review and report of four new cases. Medicine (Baltimore) 1982;61:13-24.
76. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxford) 1997;46:263-8.
77. Oelkers W, L'age M. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement. Klin Wochenschr 1976;54:607-12.
78. Smith SJ, MacGregor GA, Markandu ND, et al. Evidence that patients with Addison's disease are undertreated with fludrocortisone. Lancet 1984;1:11-4.
79. Ram CV. Pheochromocytoma. Cardial Clin 1988;6:517- 35.
80. Cryer PE. Diseases of the sympathochromaffin system. In: Felig P, Frohman LA, eds. Endocrinology and metabolism. New York: McGraw-Hill, 2001:525-51.
81. Bravo EL, Gifford RW Jr. Current concepts. Pheochromocytoma: diagnosis, localization and management, N Engl J Med 1984;311: 1298-303.
82. Okuda O, Umezawa H, Miyaoka M. Pituitary apoplexy caused by endocrine stimulation tests: a case report. Surg Neurol 1994;42:19-22.
83. Abbott J, Kirkby GR. Acute visual loss and pituitary apoplexy after surgery. BMJ 2004;329:218-19.
84. Ayuk J, McGregor EJ, Mitchell RD, et al. Acute management of pituitary apoplexy - surgery or conservative management? Clin Endocrinol (Oxford) 2004;61:747-52.
85. Randeva HS, Schoebel J, Byrne J, et al. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxford) 1999;51:181-8.
86. Mohr G, Hardy J. Hemorrhage, necrosis, and apoplexy in pituitary adenomas. Surg Neurol 1982;18:181-9.
87. Bills DC, Meyer FB, Laws ER Jr, et al. A retrospective analysis of pituitary apoplexy. Neurosurgery 1993;33:602-8.
88. Nielsen EH, Lindholm J, Bjerre P, et al. Frequent occurrence of pituitary apoplexy in patients with non-functioning pituitary adenoma. Clin Endocrinol (Oxford) 2006;64:319-22.
89. Randeva HS, Schoebel J, Byrne J, et al. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxford) 1999;51:181-8.
90. Kaufmann P, Lax SF, Radner H, et al. Severe hypotension and coma secondary to unrecognized chronic anterior hypophysitis. Intensive Care Med 1995;21:847-9.
91. Arafah BM, Harrington JF, Madhoun ZT, et al. Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab 1990;71:323-8.
92. Maccagnan P, Macedo CL, Kayath MJ, et al. Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab 1995;80:2190-7.